When will the FDA approve Compass Pathways' COMP360 Psilocybin?

Open

COMP360 Psilocybin for Treatment-Resistant Depression

Selected outcome

Before October 2027

87%

Before October 2027 · 87%

Stored quote · checking the venue

Scheduled end: Dec 31, 2026 ET
Resolution source: U.S. Food and Drug Administration. (opens in a new tab)

Price

Loading price history.

Markets

Before Jan 1, 2027
Will the FDA approve COMP360 Psilocybin for Treatment-Resistant Depression before Jan 1, 2027?
23%
Open · ~$22 24h · ~$1,539 vol
Bid 22¢ · Ask 23¢
Open full market view →
Before Mar 1, 2027
Will the FDA approve COMP360 Psilocybin for Treatment-Resistant Depression before Mar 1, 2027?
63%
Open · ~$6 24h · ~$2,903 vol
Bid 60¢ · Ask 65¢
Open full market view →
Before July 2027
When will the FDA approve COMP360 Psilocybin for Treatment-Resistant Depression?
84%
Open · ~$0 24h · ~$7,476 vol
Bid 81¢ · Ask 86¢
Open full market view →
Before October 2027
When will the FDA approve COMP360 Psilocybin for Treatment-Resistant Depression?
87%
Open · ~$0 24h · ~$1,932 vol
Bid 83¢ · Ask 91¢
Open full market view →
Before 2028
When will the FDA approve COMP360 Psilocybin for Treatment-Resistant Depression?
89%
Open · ~$0 24h · ~$1,022 vol
Bid 85¢ · Ask 92¢
Open full market view →

Event statistics

24h vol: ~$28
Volume: ~$15k
Liquidity: —
Open int.: 11k contracts

How this resolves

Scheduled end: Dec 31, 2026 ET
Resolution source: U.S. Food and Drug Administration. (opens in a new tab)

Trading
Closed
In review
Resolved

Rules text

If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Oct 1, 2027, then the market resolves to Yes.

Tech